We can now use such figures with confidence when discussing likely outcomes of projected procedures with our patients and, hopefully, with a clear conscience.
It may therefore come as a surprise to learn how much of our vaunted success is dependent on factors over which we have little influence but take for granted. In Britain at least our patients are still reasonably compliant. What the doctor says tends to go. It does not occur to us that patients will fail to attend for postoperative follow-up appointments, fail to use the prescribed drops, or decline to be tested for or wear necessary spectacles.
In this issue a paper by Dr Al Faran reports the results of modern cataract surgery undertaken at the King Khaled Eye Hospital in Riyadh. The study was made because the staff at the hospital considered that their results were not matching those achieved elsewhere. They report, for instance, final acuities of 6/12 (20/40) Al Faran's problems are related to factors beyond his control. The high incidence of endemic sight-impairing disease, particularly trachoma and climatic droplet keratopathy (25% in this study), are gradually being overcome with improvements in community health. In my experience droplet keratopathy is more prevalent in the poorer strata of Middle Eastern society and often superimposed on preexisting corneal scarring, due either to trachoma or smallpox.
The elimination of these conditions should therefore be followed by a similar fall in the incidence of droplet keratopathy.
The problems concerned with the refusal of large sections of a community to wear glasses where these are indicated are likely to respond only to the influence of effective universal education, and in Saudi Arabia will take one or two generations. The same applies to the reported sex differences in the patients of this study. The More than a century ofcontroversy has surrounded the cell of origin ofretinoblastoma. At the outset Virchow described the tumour as a glioma in the belief that it arose from the glial cells of the retina.' Subsequently, in a report of a single case, Flexner was the first to describe the rosettes which may be present in retinoblastomas and to designate this tumour a neuroepithelioma.2 Later still Wintersteiner described rosettes in a series of cases and substituted the term neuroepithelioma for glioma, whether or not resetting was present.3 Both authors regarded rosettes as an attempt to form photoreceptors, leading Verhoeff to suggest the description 'retinoblastoma' in order to indicate the origin of all histological variants of the tumour from embryonic retinal cells and to parallel the name 'neuroblastoma.'
The term retinoblastoma was adopted by the American Ophthalmological Society in 1926.' In the same year Bailey and Cushing produced a classification of brain tumours based on histogenesis.I The medullary epithelium lining the embryonic neural tube differentiates into three groups of cells: the neuroblastic series which gives rise to neurons, the spongioblastic series which forms the glia, and the medulloblastic series of cells which are primitive and undifferentiated and which may lead to either glia or neurons. Using gold and silver stains they classified each tumour according to the type of cell predominating. Several attempts were made to apply the same principles to retinoblastoma.1'0 Using silver impregnated preparations, Mufioz-Urra identified spongioblasts as well as astroblasts and astrocytes in the histogenesis of retinoblastoma. 6 Parkhill and Benedict could not demonstrate any cell processes or fibrils indicative either ofglia or of neurons using special stains and regarded the cells they saw as primitive and undifferentiated. 33 35-3' have indicated both a neuronal and a glial origin for retinoblastoma.
In their article in the present issue of the BJO Tarlton and Easty have further explored the immunohistological reactivity of retinoblastoma using a panel of monoclonal antibodies to achieve a more specific immunolocalisation. Their data suggest that the tumour arises from an early multipotential cell with the capacity to develop into an inner or outer retinal cell so that the resultant tumour cell population is heterogeneous.
JOHN HUNGERFORD 
